An open-label study was carried out in 2016 in the united kingdom to research the feasibility, safety and efficacy of psilocybin in treating sufferers with unipolar treatment-resistant depression with promising final results; although the study was small and concerned only twelve sufferers, 7 of People patients achieved formal criteria for remissio